Ondansetron Safety in Pregnancy
Ondansetron is safe and effective for use during pregnancy, particularly as a second-line antiemetic when first-line agents fail, and women can be reassured about the very small absolute increase in orofacial cleft risk that must be balanced against the significant harms of poorly controlled nausea and vomiting. 1
Treatment Algorithm
First-Line Antiemetics (Use These First)
- Antihistamines (H1 antagonists): promethazine, cyclizine, cinnarizine
- Phenothiazines: prochlorperazine, chlorpromazine
- Pyridoxine-doxylamine (Xonvea®)
These have extensive safety data showing no increased risk of congenital malformations or adverse pregnancy outcomes 1.
Second-Line: Ondansetron (When First-Line Fails)
Use ondansetron without hesitation if first-line agents are ineffective. The guideline explicitly states its use "should not be discouraged" 1.
The Orofacial Cleft Risk in Context
The absolute risk increase is minimal and clinically manageable:
- Background risk: 11 cases per 10,000 births
- With ondansetron: 14 cases per 10,000 births
- Absolute increase: 3 additional cases per 10,000 births 1
This represents an adjusted relative risk of 1.24 (95% CI 1.03-1.48) from the largest study of 88,467 first-trimester exposures 1. Importantly, this small increase must be weighed against the substantial risks of uncontrolled hyperemesis gravidarum, including dehydration, electrolyte disturbances, weight loss, and even termination of pregnancy 1.
Cardiac Defects: Reassuring Data
The most robust study (1.8 million pregnancies, 88,467 ondansetron exposures) found no significant association with cardiac defects after adjusting for confounders (adjusted RR 0.99,95% CI 0.93-1.06) 1. While one smaller study suggested increased cardiac septal defects, this was not confirmed in other studies 2.
Overall Malformation Risk: No Increase
Over 97,000 first-trimester exposures across 12 studies, including meta-analyses, show no increased overall malformation rate compared to disease-matched or unexposed controls 1. The UK Teratology Information Service systematic review explicitly concluded that available data "do not provide evidence that ondansetron use in the first trimester of pregnancy is associated with an increase in the overall malformation rate" 1.
Recent prospective studies continue to support safety, showing no differences in major congenital malformations (5.1% vs 4.1%, p=0.695), live birth rates, or neonatal complications 3. A large multinational cohort of 456,963 pregnancies found no association with fetal death (adjusted HR 0.91,95% CI 0.67-1.23), spontaneous abortion, stillbirth, or major malformations (OR 1.06,95% CI 0.91-1.22) 4.
Regulatory Context
The UK MHRA did not issue a warning against ondansetron use in pregnancy, unlike the European Medicines Authority 1. The FDA label acknowledges inconsistent findings but notes that epidemiological studies have important methodological limitations that "preclude conclusions about the safety of ondansetron use in pregnancy" 2.
Critical Counseling Points
When prescribing ondansetron:
- Explain the very small absolute risk increase in orofacial clefts (3 per 10,000)
- Emphasize that poorly controlled hyperemesis poses greater risks to both mother and fetus
- Note that one study comparing women with hyperemesis found higher termination rates in those NOT taking ondansetron and higher live birth rates in those taking it 1
- Reassure that no overall increase in malformations has been demonstrated
Common Pitfalls to Avoid
- Don't withhold ondansetron due to fear of litigation: The evidence supports its safety, and untreated hyperemesis carries real morbidity
- Don't confuse relative risk with absolute risk: A 24% relative increase sounds alarming, but translates to only 3 additional cases per 10,000 births
- Don't ignore confounding by indication: Women with severe nausea/vomiting may have different baseline risks; studies comparing ondansetron users to other women with hyperemesis show no increased malformation risk 1